Alamarbio
Fremont, US · Founded 2018 · 243 employees on LinkedIn · 3 known investors
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope). The company serves proteomics research and clinical drug development applications.
Founders & leadership
Alamarbio was founded in 2018 by Yuling Luo, Steve Chen, and Yiyuan Yin.
Investors · 3
Competitors · 2
by search overlap
Companies competing with Alamarbio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $321.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Alamarbio do?
- Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope). The company serves proteomics research and clinical drug development applications.
- Who founded Alamarbio?
- Alamarbio was founded by Yuling Luo, Steve Chen, Yiyuan Yin in 2018.
- Who are Alamarbio's investors?
- Alamarbio's investors include Illumina Ventures, Qiming Venture Partners, Samsara BioCapital.
- Where is Alamarbio headquartered?
- Alamarbio is headquartered in Fremont, US.